Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

I have a friend who goes to a ketamine clinic for fun. He doesn’t have depression or PTSD, but heard that ketamine was a ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, ... Esketamine, the S-enantiomer of ketamine, was approved by the FDA in 2019 for the treatment of TRD.

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Home; Articles; The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors ...

Esketamine nasal spray (Spravato) monotherapy was helpful in improving symptoms of treatment-resistant depression, a randomized, double-blind trial found. Among 379 participants in the efficacy ...

Esketamine combined with an SNRI is more effective for treatment-resistant depression (TRD) than when paired with an SSRI. Analysis of over 55,000 patients showed that the SNRI combination ...

The FDA first approved esketamine nasal spray for treatment-resistant depression in combination with an oral antidepressant, as reported by Medscape Medical News.. The expanded indication as ...

During the 4-week treatment period, adults ages 22 to 64 (mean age 42-43, 86% women, 78% white) without psychotic features of DSM-5-confirmed MDD participated in three CT-152 or sham sessions per ...

My mission is to deliver compassionate, personalized, and innovative care, empowering you to reclaim your mental health, improve your overall well-being and elevate your quality of life.